Disease areas
Cardiology
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
Cardiometabolic
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
Eye Disease
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
Infectious disease
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
Neurology
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
Oncology
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
Cardiology
See all →
Africa’s Cardiovascular Decade Is a System-Design Problem
Inherited Lipid Screening Becomes Europe’s Prevention Test
ATTR Gene Editing Restarts, But Safety Becomes the Access Question
Routine CT Scans Could Become a Heart Failure Early-Warning System
Risk Prediction Cannot Simply Be Imported From Europe
Personalised Cardiology Needs a Digital Fabric, Not Just More Data
Cardiometabolic
See all →
Europe’s Safe Hearts Plan Makes Prevention a Political Test
AI Diabetes Tools Need Infrastructure Before Scale
Diabetes Tech Moves From Optional Add-On to Earlier Care
Obesity Care Starts Moving Beyond BMI
Canada’s Generic Semaglutide Approval Tests GLP-1 Affordability
India’s Obesity Campaign Dispute Tests the Line Between Awareness and Promotion
England’s Tirzepatide Rollout Shows Approval Is Not Access
Medicare’s GLP-1 Bridge Turns Obesity Coverage Into a Public-Payer Experiment
WHO Makes Obesity Treatment a Global Access Test
Eye Disease
See all →
Diabetic Eye Screening Is Becoming Risk-Based
Abu Dhabi Puts Rare Eye Gene Therapy on the Regional Map
AI Eye Screening Has an Image Quality Problem
AI Retinal Screening Moves Into the Diabetes Clinic
Geographic Atrophy Forces Europe to Define Meaningful Vision Benefit
Eye Health Moves From Charity Case to Investment Case
Infectious disease
See all →
Neurology
See all →
AI in Cardiology Moves From Promise to Policy Pressure
Cyberbullying Becomes a Youth Mental Health Policy Target
Alzheimer’s Agitation Gets a New Drug, But Care Pathways Still Lag
Rare Epilepsy Moves Toward Treating the Cause
Huntington Gene Therapy Hits the Evidence Wall
Rare Disease Policy Moves Into the Individualised Therapy Era
Digital Mental Health Still Has an Evidence Problem
Alzheimer’s Access Now Starts With Genotyping and MRI Capacity
Europe’s Mental Health Projects Move From Crisis Talk to Delivery Tools
Europe’s Epilepsy Rules Start Catching Up With Precision Treatment
Oncology
See all →
Oncology Trials Still Do Not Match the Patients They Will Treat
Cancer Pharmacogenomics Exposes an Ancestry Gap in Routine Testing
Biomarker Testing Is Rising, But Eligibility Still Gets Lost
Colon Cancer MRD Testing Is Nearing the Access Threshold
Breast Cancer Blood Tests Could Bring Treatment Decisions Earlier
Lung Cancer Screening Now Has a Diagnostic Bottleneck
Liquid Biopsy Turns Precision Oncology Into an NHS Delivery Test
Molecular Testing Is Europe’s Real Precision Oncology Infrastructure
Cancer Approval Is No Longer Enough
